Literature DB >> 34713920

Astrocytic VEGFA: An essential mediator in blood-brain-barrier disruption in Parkinson's disease.

Guoyu Lan1, Pan Wang2,3, Robin Barry Chan4, Zongran Liu1, Zhenwei Yu5, Xiaodan Liu1, Ying Yang1, Jing Zhang2,3.   

Abstract

The integrity of blood-brain-barrier (BBB) is essential for normal brain functions, synaptic remodeling, and angiogenesis. BBB disruption is a common pathology during Parkinson's disease (PD), and has been hypothesized to contribute to the progression of PD. However, the molecular mechanism of BBB disruption in PD needs further investigation. Here, A53T PD mouse and a 3-cell type in vitro BBB model were used to study the roles of α-synuclein (α-syn) in BBB disruption with the key results confirmed in the brains of PD patients obtained at autopsy. The A53T PD mouse studies showed that the expression of tight junction-related proteins decreased, along with increased vascular permeability and accumulation of oligomeric α-syn in activated astrocytes in the brain. The in vitro BBB model studies demonstrated that treatment with oligomeric α-syn, but not monomeric or fibrillar α-syn, resulted in significant disruption of BBB integrity. This process involved the expression and release of vascular endothelial growth factor A (VEGFA) and nitric oxide (NO) from oligomeric α-syn treated astrocytes. Increased levels of VEGFA and iNOS were also observed in the brain of PD patients. Blocking the VEGFA signaling pathway in the in vitro BBB model effectively protected the barrier against the harmful effects of oligomeric α-syn. Finally, the protective effects on BBB integrity associated with inhibition of VEGFA signaling pathway was also confirmed in PD mice. Taken together, our study concluded that oligomeric α-syn is critically involved in PD-associated BBB disruption, in a process that is mediated by astrocyte-derived VEGFA.
© 2021 Wiley Periodicals LLC.

Entities:  

Keywords:  NO; Parkinson's disease; VEGFA; astrocytes; blood-brain-barrier; iNOS; α-Synuclein

Mesh:

Substances:

Year:  2021        PMID: 34713920     DOI: 10.1002/glia.24109

Source DB:  PubMed          Journal:  Glia        ISSN: 0894-1491            Impact factor:   7.452


  8 in total

1.  VEGFA mediates blood-brain barrier disruption in Parkinson disease.

Authors:  Heather Wood
Journal:  Nat Rev Neurol       Date:  2022-01       Impact factor: 42.937

Review 2.  The Emerging Role of Central and Peripheral Immune Systems in Neurodegenerative Diseases.

Authors:  Xin Zang; Si Chen; JunYao Zhu; Junwen Ma; Yongzhen Zhai
Journal:  Front Aging Neurosci       Date:  2022-04-25       Impact factor: 5.702

Review 3.  The blood-brain barrier in aging and neurodegeneration.

Authors:  Emily G Knox; Maria R Aburto; Gerard Clarke; John F Cryan; Caitriona M O'Driscoll
Journal:  Mol Psychiatry       Date:  2022-03-31       Impact factor: 13.437

Review 4.  Microvascular Changes in Parkinson's Disease- Focus on the Neurovascular Unit.

Authors:  Gesine Paul; Osama F Elabi
Journal:  Front Aging Neurosci       Date:  2022-03-10       Impact factor: 5.750

5.  VEGF Paradoxically Reduces Cerebral Blood Flow in Alzheimer's Disease Mice.

Authors:  Muhammad Ali; Oliver Bracko
Journal:  Neurosci Insights       Date:  2022-07-04

6.  Immunohistochemical Demonstration of the pGlu79 α-Synuclein Fragment in Alzheimer's Disease and Its Tg2576 Mouse Model.

Authors:  Alexandra Bluhm; Sarah Schrempel; Stephan Schilling; Stephan von Hörsten; Anja Schulze; Steffen Roßner; Maike Hartlage-Rübsamen
Journal:  Biomolecules       Date:  2022-07-20

Review 7.  Role of Glial Cell-Derived Oxidative Stress in Blood-Brain Barrier Damage after Acute Ischemic Stroke.

Authors:  Xiaoyan Hu; Yanping Wang; Weihong Du; Li-Jun Liang; Wei Wang; Xinchun Jin
Journal:  Oxid Med Cell Longev       Date:  2022-09-02       Impact factor: 7.310

8.  Single-cell RNA sequencing of CSF reveals neuroprotective RAC1+ NK cells in Parkinson's disease.

Authors:  Qing Guan; Wei Liu; Ketao Mu; Qi Hu; Jiazhao Xie; Liming Cheng; Xiong Wang
Journal:  Front Immunol       Date:  2022-09-21       Impact factor: 8.786

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.